Navigation Links
MedImmune Focused on Revolutionizing Cancer Care
Date:11/16/2010

GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

"At MedImmune, we are thinking about cancer and treatment in new ways, using insights and understanding of the disease to discover breakthrough biologic therapies that can be used to treat specific cancers for the individual patient," said Jerry McMahon, Senior Vice President and Oncology Innovative Medicines Unit Leader.  "We are excited about the progress of the oncology portfolio and are looking forward to its advancement of multiple oncology products into expanded clinical studies in the near future."  

With innovative antibody and biologic technologies, the MedImmune Oncology pipeline is focusing on developing new therapies to eliminate cancer cells in more effective and targeted ways.  This research is addressing the key areas critical to the development and progression of cancer: immune-mediated killing, vascular modulation, growth factor, and survival signaling.  

"The identification of novel cancer drug targets and associated biologic markers has not only altered the way we view cancer, but is truly revolutionizing our standard of care," said Bahija Jallal, Executive Vice President Research and Development at MedImmune.  "It is this research, with products like moxetumomab pasudotox (CAT-8015), that will help develop more effective solutions to targeting malignant tumor cells and providing a more personalized approach to medicine."

New data presentations

Four MedImmune-sponsored posters are being presented at the 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" starting on Tuesday, November 16 in Berlin.  EORTC-NCI-AACR is a joint meeting of the European Organisation for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research.  These abstracts include:

  • Glioblastoma multiforme is characterized by high incidence of PDGFR-alpha expression and susceptibility to the PDGFR-alpha-specific antibody MEDI-575 in mouse tumor models – presented by Dr. Philipp Steiner, on Wednesday, November 17

  • Inhibition of PDGFR-alpha in tumor stroma with MEDI-575 enhances activity of carboplatin/  paclitaxel and delays tumor regrowth in a NSCLC xenograft model – presented by Dr. Philipp Steiner, on Wednesday, November 17

  • Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors – presented by Dr. Robert Lechleider, on Thursday, November 18

  • MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a phase 1 study for advanced solid tumors –presented by Dr. Michael Menefee, on Thursday, November 18

Then in December, two MedImmune-sponsored posters are being presented at the 52nd ASH (American Society of Hematology) starting on Saturday, December 4 in Orlando, including:

  • A phase I study of moxetumomab pasudotox (CAT-8015), an anti-CD22 recombinant immunotoxin, in relapsed/ refractory hairy cell leukemia (HCL): updated results – presented by Dr. Robert Kreitman, on Sunday, December 5

  • Complete remissions in 3 of 12 patients with chemotherapy-refractory pediatric acute lymphoblastic leukemia (ALL) during phase I testing of the anti-CD22 immunotoxin moxetumomab pasudotox (CAT-8015)– presented by Dr. Alan Wayne, on Monday, December 6

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
2. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
3. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
4. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
5. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
6. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor in ... address potential cybersecurity threats before they happen. The annual list of top ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National ... is pleased to announce the organization’s Certified Strength Coach credential has earned accreditation ... Coach (CSC) program validates the competency of qualified candidates for jobs in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option ... and elastin in their face, neck, and body through a virtually pain-free, non-surgical ...
Breaking Medicine News(10 mins):